MTOR and breast carcinoma: A study manifested that combined treatment with Fin56, a ferroptosis inducer, and Torin 2, an mTOR inhibitor, could synergistically inhibit the viability of bladder cancer cells, as well as induce ferroptosis and autophagy-dependent cell death through the glutathione peroxidase 4 (GPX4) protein degradation increased.462 Moreover, metformin combined with sulfasalazine, a ferroptosis inducer, had a synergistic effect on activating ferroptosis and repressing breast cancer cell proliferation463 (Table 16).